Morgan Stanley Maintains Overweight Buy on BioNTech SE (BNTX) March 10, 2026

Morgan Stanley on March 10, 2026 maintained its Overweight and Buy calls on BioNTech SE (BNTX), keeping pressure on near-term expectations. This update anchors the latest discussion around the BNTX analyst rating and follows headline news that BofA trimmed a price target to $128. Investors should note both the maintained positive stance from Morgan Stanley and the lower target from BofA when weighing risk versus reward.

BNTX analyst rating: Summary of March 10, 2026 actions

On March 10, 2026 Morgan Stanley reaffirmed an Overweight rating and a Buy stance for BioNTech SE (BNTX). StreetInsider published both notes at 12:06 PM and 12:29 PM ET. The firm kept its constructive view while noting timing and announcement effects on near-term stock moves.

BNTX analyst rating: Price target note and BofA mention

StreetInsider carried a related headline that BofA Securities lowered a BioNTech price target to $128 on March 10, 2026. That price target cut is separate from Morgan Stanley’s maintained ratings, but it adds downward pressure on expectations. For detail see the StreetInsider coverage here BofA PT lower to $128.

BNTX analyst rating: What Morgan Stanley said about stock weakness

Morgan Stanley noted that the timing of announcements likely drove recent weakness in the share price. The firm reiterated its Overweight view while arguing the pullback reflects event timing, not a fundamental reversal. Investors should weigh that view against shorter-term volatility.

BNTX analyst rating: Implications for investors and risk

A maintained Buy or Overweight means analysts still expect relative upside versus peers, but a lower price target like $128 signals more measured gains. Investors should treat the ratings as guidance, not guarantees, and factor in clinical, regulatory, and pipeline risks before acting.

BNTX analyst rating: Historical analyst coverage context

BioNTech has held mostly positive consensus ratings in recent years, with MarketWatch showing an average target near $120.31 from 23 analysts. Morgan Stanley’s March 10, 2026 notes continue that trend of favorable coverage while the occasional target cut by peers tightens upside.

BNTX analyst rating: Stock performance and market cap context

Market moves tied to these notes were modest intraday, about 0.32% and 0.4% moves on March 10, 2026. BioNTech’s market cap stands near $20,171,807,701, which frames how analyst views influence institutional flows and index inclusion momentum.

Final Thoughts

Morgan Stanley’s March 10, 2026 decision to maintain Overweight and Buy ratings keeps analyst sentiment tilted positive for BioNTech SE. The simultaneous StreetInsider report that BofA cut its price target to $128 tempers upside, and investors should treat the BNTX analyst rating as one input among many.

Meyka AI rates BNTX with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors. For real-time analyst tracking and a full view, see BNTX on Meyka BNTX on Meyka.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.